Carlsmed CARL 深 沪
等待开盘 10-14 09:30:00 美东时间
14.47
-0.310
-2.10%
华盛通- 最 高15.00
- 今 开14.87
- 成交量 4.84万股
- 最 低 14.43
- 昨 收 14.78
- 总市值 3.95亿
- 52周最高 17.23
- 市盈率 静 --
- 换手率 0.18%
- 52周最低 8.50
- 委 比 -87.51%
- 总股本 2730.27万
- 历史最高 17.23
- 量 比 0.73
- 振 幅 3.86%
- 历史最低 8.50
- 每 手 1
- 风险率 1.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅386.16%！摩根士丹利维持TeraWulf"超配"评级，上调目标价至65美元
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从62.5美元升至65美元；摩根士丹利：维持Hut 8"超配"评级，目标价从273美元升至275美元
10-13 12:30
BTIG Maintains Buy on Carlsmed, Raises Price Target to $24
BTIG analyst Ryan Zimmerman maintains Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $23 to $24.
10-12 17:56
Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Carlsmed, Inc. granted stock options and RSUs to its new CFO, Richard Heppenstall, and Chief Product and AI Officer, Anthony Jarc, as employment inducements. The options and RSUs vest over four and three years, respectively, and were approved by the independent Compensation Committee outside the equity incentive plan, in compliance with Nasdaq rules.
10-02 20:01
Carlsmed Appoints Tony Jarc as Chief Product and AI Officer
Carlsmed, Inc. appoints Tony Jarc, Ph.D. as Chief Product and AI Officer to lead the development and commercialization of its next-generation AI-enabled personalized spine surgery solutions. Jarc, a thought leader in clinical AI, joins from Intuitive Surgical, where he built the global AI organization and pioneered clinical AI innovations. His appointment follows the recent hiring of Rich Heppenstall as CFO and Jeff Bertolini's promotion to COO, ...
10-01 13:00
美股大行评级 | 潜在涨幅919.61%！HC Wainwright上调NeuroSense Therapeutics目标价至52美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持NeuroSense Therapeutics"买入"评级，目标价从8美元升至52美元；HC Wainwright & Co.：维持艾切托"买入"评级，目标价从27美元升至34美元
09-29 08:33
BTIG Reiterates Buy on Carlsmed, Maintains $23 Price Target
BTIG analyst Ryan Zimmerman reiterates Carlsmed (NASDAQ:CARL) with a Buy and maintains $23 price target.
09-28 21:33
Carlsmed Affirms FY2026 Sales Guidance of $74.000M-$78.000M vs $74.830M Est
Carlsmed (NASDAQ:CARL) affirms FY2026 sales outlook from $74.000 million-$78.000 million to $74.000 million-$78.000 million vs $74.830 million estimate.
09-28 20:37
Carlsmed Appoints Richard Heppenstall CFO, Succeeding Leo Greenstein; Co. Reiterates FY26 Revenue Range Of $74M - $78M
Carlsmed, Inc. (Nasdaq: CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Richard Heppenstall has been appointed Chief Financial Officer, effective immediately. Mr. Heppenstall succeeds Leo Greenstein, w...
09-28 20:32
Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical
Carlsmed, Inc. filed a patent infringement lawsuit against DeGen Medical, Inc. in the U.S. District Court for the District of South Carolina, alleging infringement of eight Carlsmed patents related to spinal implants, methods, and systems. Carlsmed seeks injunctive relief and damages. The company emphasizes its commitment to protecting its intellectual property to advance personalized spine surgery solutions and improve patient outcomes.
09-15 23:00
Carlsmed appoints Jeff Bertolini as new COO
Carlsmed, Inc. ( ($CARL) ) just unveiled an announcement. On September 4, 2026,...
09-09 04:32
